Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with breast and gynecological (initially ovarian) malignancies

Next Previous
Trial Profile

Phase 1/1b study of AB928 in combination with AB122 or chemotherapy in patients with breast and gynecological (initially ovarian) malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eganelisib (Primary) ; Etrumadenant (Primary) ; Zimberelimab (Primary)
  • Indications Breast cancer; Ovarian cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 26 Jun 2018 According to an Arcus Biosciences media release, status changed from planning to recruiting.
    • 26 Jun 2018 According to an Arcus Biosciences media release, Arcus Biosciences and Infinity Pharmaceuticals will also evaluate IPI-549 in combination with AB928 + AB122 as well as IPI-549 in combination with AB928 + chemotherapy in patients with triple negative breast cancer (TNBC) or ovarian cancer in four separate cohorts as part of this trial. Each of these four cohorts will enrol approximately 15 patients.
    • 11 Jun 2018 According to the Arcus Biosciences media release, the company has been completing the regulatory process to evaluate the combination of AB928 and AB122 in patients in Australia and expects to dose its first patient with this combination shortly.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top